Premium
Production of [ 89 Zr]Oxinate 4 and cell radiolabeling for human use
Author(s) -
Massicano Adriana V.F.,
Bartels Jennifer L.,
Jeffers Charlotte D.,
Crenshaw Bryant K.,
Houson Hailey,
Mueller Christina,
Younger Jarred W.,
Knapp Paul,
McConathy Jonathan E.,
Lapi Suzanne E.
Publication year - 2021
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.3901
Subject(s) - chemistry , radiochemistry , pet imaging , positron emission tomography , cell , viability assay , nuclear medicine , biochemistry , medicine
[ 89 Zr]Oxinate 4 is a Positron Emission Tomography (PET) tracer for cell radiolabeling that can enable imaging techniques to help better understand cell trafficking in various diseases. Although several groups have synthetized this compound for use in preclinical studies, there is no available data regarding the production of [ 89 Zr]Oxinate 4 for human use. In this report, we describe the detailed production of [ 89 Zr]Oxinate 4 under USP <823> and autologous leukocyte radiolabeling under USP <797>. The final product presented high radiochemical purity and stability at 24 h post synthesis (>99%) and passed in all quality control assays required for clinical use. [ 89 Zr]Oxinate 4 did not compromise the white blood cells viability and did not show considerable cellular efflux up to 3 h post labeling. The translation of this technique into human use can provide insight into several disease mechanisms since [ 89 Zr]Oxinate 4 has the potential to label any cell subset of interest.